Preventing leptin resistance by blocking angiotensin II at1 receptors in diet-induced obese rats

British Journal of Pharmacology

Volumn 172, Issue 3, 2015, Pages 857-868

  Müller Fielitz, Helge ^a,b   Lau, Margot ^a   Geißler, Cathleen ^a   Werner, Lars ^a   Winkler, Martina ^a   Raasch, Walter ^a,b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; LEPTIN; STAT3 PROTEIN; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; DIET INDUCED OBESITY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FOOD INTAKE; HEART RATE; HORMONE BLOOD LEVEL; HORMONE RESISTANCE; HORMONE SENSITIVITY; HORMONE TRANSPORT; LEPTIN BLOOD LEVEL; LEPTIN RESISTANCE; NONHUMAN; PREVENTION STUDY; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WEIGHT REDUCTION; ADVERSE EFFECTS; ANIMAL; BLOOD; DIET; METABOLISM; OBESITY; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DIET; LEPTIN; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 84920849552     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12949     Document Type: Article

References (65)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
4. Awad AS (2006). Role of AT1 receptors in permeability of the blood-brain barrier in diabetic hypertensive rats. Vascul Pharmacol 45: 141-147.
5. Banks WA, Farrell CL (2003). Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible. Am J Physiol Endocrinol Metab 285: E10-E15.
6. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM (1996). Leptin enters the brain by a saturable system independent of insulin. Peptides 17: 305-311.
7. Banks WA, DiPalma CR, Farrell CL (1999). Impaired transport of leptin across the blood-brain barrier in obesity. Peptides 20: 1341-1345.
8. Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke R et al. (2004). Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 53: 1253-1260.
9. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M et al. (2004). Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43: 993-1002.
10. Boado RJ, Golden PL, Levin N, Pardridge WM (1998). Up-regulation of blood-brain barrier short-form leptin receptor gene products in rats fed a high fat diet. J Neurochem 71: 1761-1764.
11. Burguera B, Couce ME, Curran GL, Jensen MD, Lloyd RV, Cleary MP et al. (2000). Obesity is associated with a decreased leptin transport across the blood-brain barrier in rats. Diabetes 49: 1219-1223.
12. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH et al. (1996). Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 348: 159-161.
13. Cason AM, Smith RJ, Tahsili-Fahadan P, Moorman DE, Sartor GC, Aston-Jones G (2010). Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity. Physiol Behav 100: 419-428.
14. Chodobski A, Szmydynger-Chodobska J (2001). Choroid plexus: target for polypeptides and site of their synthesis. Microsc Res Tech 52: 65-82.
15. Chung S, Parks GS, Lee C, Civelli O (2011). Recent updates on the melanin-concentrating hormone (MCH) and its receptor system: lessons from MCH1R antagonists. J Mol Neurosci 43: 115-121.
16. Cunningham JJ, Calles-Escandon J, Garrido F, Carr DB, Bode HH (1986). Hypercorticosteronuria and diminished pituitary responsiveness to corticotropin-releasing factor in obese Zucker rats. Endocrinology 118: 98-101.
17. Fogari R, Zoppi A, Ferrari I, Mugellini A, Preti P, Lazzari P et al. (2009). Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res 41: 893-898.
18. Guillaume-Gentil C, Rohner-Jeanrenaud F, Abramo F, Bestetti GE, Rossi GL, Jeanrenaud B (1990). Abnormal regulation of the hypothalamo-pituitary-adrenal axis in the genetically obese fa/fa rat. Endocrinology 126: 1873-1879.
19. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM (1997). Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci U S A 94: 8878-8883.
20. He H, Yang D, Ma L, Luo Z, Ma S, Feng X et al. (2010). Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-{delta}-dependent pathways. Hypertension 55: 869-879.
21. Jöhren O, Saavedra JM (1996). Expression of AT1A and AT1B angiotensin II receptor messenger RNA in forebrain of 2-wk-old rats. Am J Physiol 271: E104-E112.
22. Kamari Y, Harari A, Shaish A, Peleg E, Sharabi Y, Harats D et al. (2008). Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats. Hypertens Res 31: 135-140.
23. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
24. Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T (2007). Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 6: 12.
25. de Lartigue G, Barbier de la Serre C, Espero E, Lee J, Raybould HE (2011). Diet-induced obesity leads to the development of leptin resistance in vagal afferent neurons. Am J Physiol Endocrinol Metab 301: E187-E195.
26. Lau M, Raasch W (2012). The influence of the renin angiotensin II aldosteron system on energy intake and body weight. Adipositas 6: 110-117.
27. Maul B, Krause W, Pankow K, Becker M, Gembardt F, Alenina N et al. (2005). Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J 19: 1474-1481.
28. McAlister ED, Van Vugt DA (2004). Effect of leptin administration versus re-feeding on hypothalamic neuropeptide gene expression in fasted male rats. Can J Physiol Pharmacol 82: 1128-1134.
29. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
30. Michel MC, Foster C, Brunner HR, Liu L (2013). A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 65: 809-848.
31. Miesel A, Müller H, Thermann M, Heidbreder M, Dominiak P, Raasch W (2010). Overfeeding-induced obesity in spontaneously hypertensive rats: an animal model of the human metabolic syndrome. Ann Nutr Metab 56: 127-142.
32. Miesel A, Müller-Fielitz H, Jöhren O, Vogt FM, Raasch W (2012). Double blockade of angiotensin II (AT(1))-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats. Br J Pharmacol 165: 2721-2735.
33. Morris DL, Rui L (2009). Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 297: E1247-E1259.
34. Müller H, Schweitzer N, Jöhren O, Dominiak P, Raasch W (2007). Angiotensin II stimulates the reactivity of the pituitary-adrenal axis in leptin-resistant Zucker rats, thereby influencing the glucose utilization. Am J Physiol Endocrinol Metab 293: E802-E810.
35. Müller-Fielitz H, Raasch W (2013). Angiotensin II impairs glucose utilization in obese Zucker rats by increasing HPA activity via an adrenal-dependent mechanism. Horm Metab Res 45: 173-180.
36. Müller-Fielitz H, Markert A, Wittmershaus C, Pahlke F, Jöhren O, Raasch W (2011). Weight loss and hypophagia after high-dose AT(1)-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure. Naunyn Schmiedebergs Arch Pharmacol 383: 373-384.
37. Müller-Fielitz H, Landolt J, Heidbreder M, Werth S, Vogt FM, Jöhren O et al. (2012). Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation. Endocrinology 153: 1103-1115.
38. Müller-Fielitz H, Hübel N, Mildner M, Vogt FM, Barkhausen J, Raasch W (2014). Chronic blockade of angiotensin AT1 receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. Br J Pharmacol 171: 746-760.
39. Narayanaswami V, Somkuwar SS, Horton DB, Cassis LA, Dwoskin LP (2013). Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [(3)H]dopamine and [(3)H]norepinephrine release. Biochem Pharmacol 86: 656-665.
40. Nishiyama M, Makino S, Asaba K, Hashimoto K (1999). Leptin effects on the expression of type-2 CRH receptor mRNA in the ventromedial hypothalamus in the rat. J Neuroendocrinol 11: 307-314.
41. Noma K, Toshinaia K, Koshinaka K, Nakazato M (2011). Telmisartan suppresses food intake in mice via the melanocortin pathway. Obes Res Clin Pract 5: e79-e156.
42. Patterson CM, Bouret SG, Dunn-Meynell AA, Levin BE (2009). Three weeks of postweaning exercise in DIO rats produces prolonged increases in central leptin sensitivity and signaling. Am J Physiol Regul Integr Comp Physiol 296: R537-R548.
43. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-106.
44. Pelisch N, Hosomi N, Ueno M, Nakano D, Hitomi H, Mogi M et al. (2011). Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats. Am J Hypertens 24: 362-368.
45. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T et al. (1995). Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269: 540-543.
46. Perello M, Cakir I, Cyr NE, Romero A, Stuart RC, Chiappini F et al. (2010). Maintenance of the thyroid axis during diet-induced obesity in rodents is controlled at the central level. Am J Physiol Endocrinol Metab 299: E976-E989.
47. Plum L, Ma X, Hampel B, Balthasar N, Coppari R, Munzberg H et al. (2006). Enhanced PIP3 signaling in POMC neurons causes KATP channel activation and leads to diet-sensitive obesity. J Clin Invest 116: 1886-1901.
48. Raasch W, Bartels T, Schwartz C, Häuser W, Rütten H, Dominiak P (2002). Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors? J Hypertens 20: 2495-2504.
49. Raasch W, Wittmershaus C, Dendorfer A, Voges I, Pahlke F, Dodt C et al. (2006). Angiotensin II inhibition reduces stress sensitivity of hypothalamo-pituitary-adrenal axis in SHR. Endocrinology 147: 3539-3546.
50. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE et al. (2008). Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 105: 7257-7262.
51. Sahu A, Metlakunta AS (2005). Hypothalamic phosphatidylinositol 3-kinase-phosphodiesterase 3B-cyclic AMP pathway of leptin signalling is impaired following chronic central leptin infusion. J Neuroendocrinol 17: 720-726.
52. Scarpace PJ, Matheny M, Tumer N (2001). Hypothalamic leptin resistance is associated with impaired leptin signal transduction in aged obese rats. Neuroscience 104: 1111-1117.
53. Scheen AJ (2004). Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 30: 487-496.
54. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S et al. (2005). Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54: 3442-3452.
55. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG (2000). Central nervous system control of food intake. Nature 404: 661-671.
56. Souza-Mello V, Gregorio BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB, Mandarim-de-Lacerda CA (2010). Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond) 119: 239-250.
57. Spinedi E, Gaillard RC (1998). A regulatory loop between the hypothalamo-pituitary-adrenal (HPA) axis and circulating leptin: a physiological role of ACTH. Endocrinology 139: 4016-4020.
58. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW (2006). Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47: 1003-1009.
59. Villa L, Boor P, Konieczny A, Kunter U, van Roeyen CR, Denecke B et al. (2011). Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis. Nephrol Dial Transplant 26: 3131-3143.
60. Vital SA, Terao S, Nagai M, Granger DN (2010). Mechanisms underlying the cerebral microvascular responses to angiotensin II-induced hypertension. Microcirculation 17: 641-649.
61. Voigt JP, Raasch W, Hortnagl H, Bader M, Fink H, Jöhren O (2008). Changes in the brain serotonin satiety system in transgenic rats lacking brain angiotensinogen. J Neuroendocrinol 20: 182-187.
62. Wetzler S, Dumaz V, Goubern M, Tome D, Larue-Achagiotis C (2004). Intraperitoneal leptin modifies macronutrient choice in self-selecting rats. Physiol Behav 83: 65-72.
63. Wosik K, Cayrol R, Dodelet-Devillers A, Berthelet F, Bernard M, Moumdjian R et al. (2007). Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 27: 9032-9042.
64. Zanchi A, Dulloo AG, Perregaux C, Montani JP, Burnier M (2007). Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. Am J Physiol Endocrinol Metab 293: E91-E95.
65. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J et al. (2006). Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 552: 112-122.